Confo Therapeutics is an emerging drug discovery company built around a disruptive technology to enable the discovery of GPCR agonists. The CONFO® technology uses single domain antibodies to lock inherently unstable GPCRs in the druggable conformation and uses this stabilized complex as a superior starting point for GPCR drug discovery. 



Biotechnology

Confo Therapeutics

Cedric Ververken

Geert Degruyter

Thomas Fontaine

Andreas Busch

Stephen Dowd

Christel Menet

Frank Landolt

Paolo Vicini

Stephanie Staelens

Marc Moens

The Research and Development team at Confo Therapeutics focuses on leveraging the CONFO® technology to discover and develop novel GPCR agonists. Composed of experts in molecular engineering, protein science, and pharmacology, this team conducts advanced research to stabilize GPCRs, design new drug candidates, and optimize their efficacy and safety profiles for potential therapeutic applications.

Research and Development

Leadership Team

��

Research and Development

About

Team members

Other teams at Confo Therapeutics

Leadership Team

Research and Development

��������

Research and Development

About

Team members

Other teams at Confo Therapeutics

Leadership Team

Research and Development

��